SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari Sells 4,665 Shares

SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari sold 4,665 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $18.65, for a total transaction of $87,002.25. Following the transaction, the chief financial officer owned 251,895 shares in the company, valued at $4,697,841.75. This represents a 1.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anshul Maheshwari also recently made the following trade(s):

• On Thursday, July 2nd, Anshul Maheshwari sold 3,317 shares of SiBone stock. The stock was sold at an average price of $16.77, for a total value of $55,626.09.

SiBone Stock Performance

Shares of NASDAQ SIBN opened at $19.14 on Wednesday. The stock has a fifty day moving average price of $17.22 and a two-hundred day moving average price of $15.25. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.55 and a current ratio of 9.15. The firm has a market cap of $848.86 million, a P/E ratio of -56.29 and a beta of 0.66. SiBone has a 1 year low of $11.48 and a 1 year high of $21.89.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.06. The company had revenue of $56.01 million for the quarter, compared to analysts’ expectations of $55.34 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. Research analysts forecast that SiBone will post -0.4 EPS for the current fiscal year.

Institutional Trading of SiBone

Institutional investors and hedge funds have recently bought and sold shares of the stock. ANTIPODES PARTNERS Ltd acquired a new position in shares of SiBone in the fourth quarter worth about $29,000. Versant Capital Management Inc raised its holdings in shares of SiBone by 102.9% during the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after acquiring an additional 887 shares during the period. Royal Bank of Canada lifted its position in shares of SiBone by 98.5% in the 4th quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock valued at $29,000 after acquiring an additional 736 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its position in shares of SiBone by 64,700.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock valued at $38,000 after acquiring an additional 1,941 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in SiBone in the 4th quarter worth approximately $53,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

Analysts Set New Price Targets

SIBN has been the subject of a number of research analyst reports. UBS Group upped their price target on shares of SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Weiss Ratings cut shares of SiBone from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 5th. TD Cowen boosted their target price on shares of SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Finally, Truist Financial restated a “buy” rating and set a $23.00 target price (up from $21.00) on shares of SiBone in a report on Tuesday, August 4th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $24.17.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.